Boston Scientific (BSX) Depreciation & Amortization (CF) (2020 - 2026)

Boston Scientific has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $355.0 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 5.65% year-over-year to $355.0 million; the TTM figure through Jun 2026 stood at $1.4 billion (up 7.45% YoY), while the FY2025 annual figure was $1.4 billion, up 7.8% from the prior year.
• Depreciation & Amortization (CF) came in at $355.0 million for Q2 2026 at Boston Scientific, up from $351.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $365.0 million in Q4 2025 to a low of $274.0 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $315.3 million, with a median of $308.5 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) rose 1.38% in 2022 and grew 11.76% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $294.0 million in 2022, then advanced by 6.46% to $313.0 million in 2023, then increased by 11.18% to $348.0 million in 2024, then grew by 4.89% to $365.0 million in 2025, then dropped by 2.74% to $355.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $355.0 million in Q2 2026, $351.0 million in Q1 2026, and $365.0 million in Q4 2025.